NEW YORK(GenomeWeb) – BG Medicine said after the close of the market on Friday that it has received a notice of non-compliance from Nasdaq indicating that the company's stock is subject to delisting unless it makes a timely request for a hearing before the Nasdaq Listing Qualifications Panel. 

BG Medicine said that it will request a hearing at which it will present its plan to regain and maintain compliance with the applicable listing requirements. The company's stock will continue to trade on Nasdaq pending the hearing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.